Theriva Biologics Stock Analysis

Theriva Stock Analysis Notes

About 21.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.14. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Theriva Biologics recorded a loss per share of 32.59. The entity last dividend was issued on the 13th of August 2018. The firm had 1:25 split on the 26th of August 2024. Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Theriva Biologics Inc. is headquartered in Rockville, Maryland. Theriva Biologics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 16 people. To find out more about Theriva Biologics contact Steven CPA at 301 417 4364 or learn more at https://therivabio.com.

Theriva Biologics Investment Alerts

Theriva Biologics Upcoming and Recent Events

Theriva Largest EPS Surprises

View All Earnings Estimates

Theriva Biologics Thematic Classifications

Theriva Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.62 M.

Theriva Profitablity

Management Efficiency

Theriva Biologics has return on total asset (ROA) of (0.2498) % which means that it has lost $0.2498 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5906) %, meaning that it created substantial loss on money invested by shareholders. Theriva Biologics' management efficiency ratios could be used to measure how well Theriva Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.65 in 2024. Return On Capital Employed is likely to rise to -0.42 in 2024. At this time, Theriva Biologics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.2 M in 2024, whereas Total Current Assets are likely to drop slightly above 14.4 M in 2024.

Technical Drivers

As of the 11th of December 2024, Theriva Biologics has the Variance of 104.38, coefficient of variation of (805.38), and Risk Adjusted Performance of (0.08). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Theriva Biologics, as well as the relationship between them.

Theriva Biologics Price Movement Analysis

Theriva Biologics Insider Trading Activities

Theriva Biologics Predictive Daily Indicators

Theriva Biologics Forecast Models

Theriva Biologics' time-series forecasting models are one of many Theriva Biologics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Theriva Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Theriva Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Theriva shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Theriva Biologics. By using and applying Theriva Stock analysis, traders can create a robust methodology for identifying Theriva entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Theriva analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Theriva analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Theriva Biologics stock analysis indicators help investors evaluate how Theriva Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Theriva Biologics shares will generate the highest return on investment. By understating and applying Theriva Biologics stock analysis, traders can identify Theriva Biologics position entry and exit signals to maximize returns.

When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.